Article
A new strategy for mapping epitopes of LACK and PEPCK proteins of Leishmania amazonensis specific for major histocompatibility complex class I
Registro en:
SENA, Edlainne Pinheiro Ferreira et al.A new strategy for mapping epitopes of LACK and PEPCK proteins of Leishmania amazonensis specific for major histocompatibility complex class I. International Journal of Molecular Sciences, v. 24, 5972, p. 1-15, Mar. 2023.
1422-0067
10.3390/ ijms24065972
Autor
Sena, Edlainne Pinheiro Ferreira
Hardoim, Daiana de Jesus
Cardoso, Flavia de Oliveira
d’Escoffier, Luiz Ney
Soares, Isabela Ferreira
Carvalho, João Pedro Rangel da Silva
Angnes, Ricardo Almir
Fragoso, Stenio Perdigão
Alves, Carlos Roberto
De Simone, Salvatore Giovanni
Lima Junior, Josué da Costa
Bertho, Alvaro Luiz
Valle, Tânia Zaverucha do
Silva, Franklin Souza da
Calabrese, Kátia da Silva
Resumen
Leishmaniasis represents a complex of diseases with a broad clinical spectrum and epidemiological
diversity, considered a major public health problem. Although there is treatment, there are
still no vaccines for cutaneous leishmaniasis. Because Leishmania spp. is an intracellular protozoan
with several escape mechanisms, a vaccine must provoke cellular and humoral immune responses.
Previously, we identified the Leishmania homolog of receptors for activated C kinase (LACK) and
phosphoenolpyruvate carboxykinase (PEPCK) proteins as strong immunogens and candidates for the
development of a vaccine strategy. The present work focuses on the in silico prediction and characterization
of antigenic epitopes that might interact with mice or human major histocompatibility complex
class I. After immunogenicity prediction on the Immune Epitope Database (IEDB) and the Database of
MHC Ligands and Peptide Motifs (SYFPEITHI), 26 peptides were selected for interaction assays with
infected mouse lymphocytes by flow cytometry and ELISpot. This strategy identified nine antigenic
peptides (pL1-H2, pPL3-H2, pL10-HLA, pP13-H2, pP14-H2, pP15-H2, pP16-H2, pP17-H2, pP18-H2,
pP26-HLA), which are strong candidates for developing a peptide vaccine against leishmaniasis.